ID   TGBC24TKB
AC   CVCL_1770
SY   TGBC-24-TKB; YoMi
DR   CLO; CLO_0050018
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472177
DR   Cell_Model_Passport; SIDM00267
DR   ChEMBL-Cells; CHEMBL3308856
DR   ChEMBL-Targets; CHEMBL2366093
DR   Cosmic; 910695
DR   Cosmic; 2629285
DR   Cosmic-CLP; 910695
DR   DepMap; ACH-002312
DR   EGA; EGAS00001000978
DR   GDSC; 910695
DR   GEO; GSM1670541
DR   IARC_TP53; 27262
DR   LINCS_LDP; LCL-1344
DR   PharmacoDB; TGBC24TKB_1591_2019
DR   RCB; RCB1196
DR   Wikidata; Q54972239
RX   PubMed=20164919;
RX   PubMed=21451941;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=32899426;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=75.8%; East Asian, South=23.94%; South Asian=0%; European, North=0.26%; European, South=0% (PubMed=30894373).
CC   Derived from metastatic site: Ascites.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 9,10
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3844; Gallbladder carcinoma
DI   ORDO; Orphanet_56044; Carcinoma of gallbladder and extrahepatic biliary tract
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 31
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21451941; DOI=10.1007/s00534-011-0376-7;
RA   Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y.,
RA   Tsuchiya T., Gotoh M.;
RT   "Gene expression analysis for predicting gemcitabine resistance in
RT   human cholangiocarcinoma.";
RL   J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Bermejo J.L.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//